news
Usona Submits Psilocybin Drug Application to FDA for Depression
Nonprofit research group Usona Institute filed a New Drug Application with the FDA for its synthetic psilocybin candidate treating major depressive disorder. It marks only the second psychedelic therapy to enter formal FDA review, following the agency's rejection of MDMA earlier this year. The submission sets up a potential regulatory decision on single-dose psilocybin within ten to twelve months.
Nonprofit research group Usona Institute filed a New Drug Application with the FDA for its synthetic psilocybin candidate treating major depressive disorder. It marks only the second psychedelic therapy to enter formal FDA review, following the agency's rejection of MDMA earlier this year. The submission sets up a potential regulatory decision on single-dose psilocybin within ten to twelve months.
The architecture take
A nonprofit beating venture-backed pharma to an FDA desk with a single-dose psychiatric drug is wild. I spent years watching biotech startups promise proprietary salt formulations and branded clinic networks, only for an open-science outfit to deliver clean trial data on unpatented psilocybin. The mechanism relies on intense 5-HT2A receptor agonism that temporarily quiets the brain's default mode network, prompting rapid synaptic plasticity rather than daily serotonin reuptake inhibition. Efficacy is the easy part. Protocol design is the headache. The FDA turned down Lykos Therapeutics largely over functional unblinding and therapist training standards. Now Usona has to prove that an eight-hour altered state can run safely in an outpatient room without requiring fifty hours of specialized psychotherapy that insurers refuse to cover. Compass Pathways is right behind them with commercial capital, but Usona got its paperwork stamped first. Watch how the advisory committee handles the unblinding question this time.